Plasma levels of 25-hydroxyvitamin D3 and In Vivo markers of cytochrome P450 3A activity in Swedes and Koreans: Effects of a genetic polymorphism and oral contraceptives

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 4, 2014, Pages 366-371

  Nylén, Hanna ^a   Björkhem Bergman, Linda ^a   Ekström, Lena ^a   Roh, Hyung Keun ^b   Bertilsson, Leif ^a   Eliasson, Erik ^a   Lindh, Jonatan D ^a   Diczfalusy, Ulf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CALCIFEDIOL; CHOLESTEROL; CYTOCHROME P450 3A; DEBRISOQUINE; GENOMIC DNA; LOSARTAN; MIDAZOLAM; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; QUININE; VITAMIN D; VITAMIN D RECEPTOR; 6 BETA-HYDROXYCORTISOL; BIOLOGICAL MARKER; CALCITRIOL RECEPTOR; CHOLEST-5-ENE-3,4-DIOL; CHOLESTEROL DERIVATIVE; HYDROCORTISONE;

ADULT; ARTICLE; CALCIUM METABOLISM; DRUG CLEARANCE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IN VIVO STUDY; KOREAN (PEOPLE); LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL CONTRACEPTIVE USE; PLASMA; SWEDE (PEOPLE); VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CAUCASIAN; GENETICS; METABOLISM; MULTIVARIATE ANALYSIS; PHENOTYPE; SOUTH KOREA; STATISTICAL MODEL; SWEDEN; TANDEM MASS SPECTROMETRY; URINE;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHOLESTEROL; CHROMATOGRAPHY, LIQUID; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; HYDROCORTISONE; HYDROXYCHOLESTEROLS; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; REPUBLIC OF KOREA; SWEDEN; TANDEM MASS SPECTROMETRY; VITAMIN D;

EID: 84908666728     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12230     Document Type: Article

References (30)

1. Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc 2012;71:50-61.
2. ZasloffM. Fighting infections with vitamin D. Nat Med 2006;12:388-90.
3. O'Keefe JH, Lavie CJ, Holick MF. Vitamin D supplementation for cardiovascular disease prevention. JAMA 2011;306:1546-7; author reply 7-8.
4. Kohli NR, Van Valkengoed IGM, Nicolaou M, Brewster LM, Van Der ADL, Stronks K et al. Vitamin D status partly explains ethnic differences in blood pressure: the 'Surinamese in the Netherlands: study on ethnicity and health'. J Hypertens 2012;30:1581-7.
5. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997;51:741-54.
6. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002;277:25125-32.
7. DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J 1988;2:224-36.
8. Carlberg C, Seuter S. A genomic perspective on vitamin D signaling. Anticancer Res 2009;29:3485-93.
9. Wang K, Chen S, Xie W, Wan YJ. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 2008;75:2204-13.
10. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357: 266-81.
11. Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP. Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr 2011;50:305-12.
12. Lindh JD, Andersson ML, Eliasson E, Björkhem-Bergman L. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos 2011;39:933-7.
13. Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N et al. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol 2012;84:104-12.
14. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003;73:517-28.
15. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H et al. 4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans. Swedes and Tanzanians. Pharmacogenet Genomics 2008;18:201-8.
16. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C et al. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001;276:38685-9.
17. Diczfalusy U, Nylén H, Elander P, Bertilsson L. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 2011;71:183-9.
18. Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB et al. Comparison of endogenous 4βhydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos 2013;41:1488-93.
19. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 2008;88:507S-10S.
20. Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB et al. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Pharmacokinet 2014; in press.
21. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009;67:38-43.
22. Khan AA, Chow ECY, van Loenen-Weemaes AMMA, Porte RJ, Pang KS, Groothuis GMM. Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur J Pharm Sci 2009;37: 115-25.
23. Xu Y, Iwanaga K, Zhou C, Chessman MJ, Farin FM, Thummel KE. Selective induction of intestinal CYP3A23 by 1a,25-dihydroxyvitamin D3 in rats. Biochem Pharmacol 2006;72:385-92.
24. Björkhem-Bergman L, Nylén H, Norlin AC, Lindh JD, Ekstrom L, Eliasson E et al. Serum Levels of 25-Hydroxyvitamin D and the CYP3A Biomarker 4β-Hydroxycholesterol in a High-Dose Vitamin D Supplementation Study. Drug Metab Dispos 2013;41:704-8.
25. Lee EY, Kim D, Kim KM, Kim KJ, Choi HS, Rhee Y et al. Agerelated bone mineral density patterns in Koreans (KNHANES IV). J Clin Endocrinol Metab 2012;97:3310-8.
26. Darling AL, Hart KH, Macdonald HM, Horton K, Kang'ombe AR, Berry JL et al. Vitamin D deficiency in UK South Asian Women of childbearing age: a comparative longitudinal investigation with UK Caucasian women. Osteoporos Int 2013;24:477-88.
27. Guessous I, Dudler V, Glatz N, Theler J, Zoller O, Paccaud F et al. Vitamin D levels and associated factors: a population-based study in Switzerland. Swiss Med Wkly 2012;142:w13719.
28. Sulistyoningrum DC, Green TJ, Lear SA, Devlin AM. Ethnic-Specific Differences in Vitamin D Status Is Associated with Adiposity. PLoS ONE 2012;7:e43159.
29. Møller U, Streym S, Jensen L, Mosekilde L, Schoenmakers I, Nigdikar S et al. Increased plasma concentrations of vitamin d metabolites and vitamin d binding protein in women using hormonal contraceptives: a cross-sectional study. Nutrients 2013;5:3470-80.
30. Horst R, Prapong S, Reinhardt T, Koszewski N, Knutson J, Bishop C. Comparison of the relative effects of 1,24-dihydroxyvitamin D (2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH) (2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat. Biochem Pharmacol 2000;60:701-8.